Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Common Equity (2022 - 2025)

Historic Common Equity for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $8.9 million.

  • bioAffinity Technologies' Common Equity rose 18523.32% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 18523.32%. This contributed to the annual value of $2.6 million for FY2024, which is 4640.78% down from last year.
  • bioAffinity Technologies' Common Equity amounted to $8.9 million in Q3 2025, which was up 18523.32% from -$2.1 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Common Equity high stood at $12.6 million for Q3 2022, and its period low was -$2.1 million during Q2 2025.
  • Its 4-year average for Common Equity is $5.8 million, with a median of $5.3 million in 2024.
  • Over the last 5 years, bioAffinity Technologies' Common Equity had its largest YoY gain of 18523.32% in 2025, and its largest YoY loss of 16222.07% in 2025.
  • bioAffinity Technologies' Common Equity (Quarter) stood at $11.0 million in 2022, then plummeted by 56.03% to $4.9 million in 2023, then tumbled by 46.41% to $2.6 million in 2024, then skyrocketed by 242.12% to $8.9 million in 2025.
  • Its Common Equity was $8.9 million in Q3 2025, compared to -$2.1 million in Q2 2025 and $1.4 million in Q1 2025.